HIV / AIDS
HIV Infection Associated with Increased Risk of Lung Cancer and Other non-AIDS Malignancies
- Details
- Category: Cancer/Malignancies
- Published on Friday, 18 May 2012 00:00
HIV positive people have about a 70% higher rate of lung cancer compared with a similar HIV negative population, according to a U.S. veterans study described in the May 15, 2012, issue of AIDS. Related studies of cancer risk presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in March also saw higher rates of non-AIDS malignancies among people with HIV.
Death Rates Decline in African Countries Receiving PEPFAR Funding
- Details
- Category: HIV Policy & Advocacy
- Published on Friday, 18 May 2012 00:00
More than 740,000 deaths may have been prevented in African countries that received intensive aid through the President’s Emergency Plan for AIDS Relief, better known as PEPFAR, according to a new analysis of more than 1.5 million people published in the May 16, 2012, Journal of the American Medical Association (JAMA).
FDA Committee Recommends Approval of First Home HIV Test
- Details
- Category: HIV Testing & Diagnosis
- Published on Wednesday, 16 May 2012 00:00
A U.S. Food and Drug Administration (FDA) advisory committee this week unanimously recommended approval of the OraQuick In-Home HIV Test. While the test can sometimes give false-negative or false-positive results, the committee decided the benefits of more people learning their HIV status outweigh the potential risks.
May 18 is HIV Vaccine Awareness Day
- Details
- Category: HIV Prevention
- Published on Wednesday, 16 May 2012 00:00
This Friday, May 18, is HIV Vaccine Awareness Day (HVAD) in the U.S. as well as World AIDS Vaccine Day, an opportunity to raise awareness about the importance of preventive HIV vaccine research and to recognize the many study volunteers, community advocates, health professionals, and researchers who are working to find safe and effective vaccines to reduce the risk of HIV infection.
FDA Advisors Favor Approval of 4-in-1 Elvitegravir Quad Pill for HIV
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 11 May 2012 00:00
On May 11, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval of Gilead Sciences' 4-in-1 once-daily single-tablet antiretroviral regimen known as the Quad. A final decision in expected by late summer.
HIV Infection Associated with Increased Risk of Sudden Cardiac Death
- Details
- Category: HIV/AIDS Mortality
- Published on Wednesday, 16 May 2012 00:00
People with HIV at a public clinic in San Francisco had a sudden cardiac death rate more than 4 times higher than that of the general population, and most who died had identifiable cardiovascular risk factors, according to a study described in the May 22, 2012, Journal of the American College of Cardiology.
FDA Advisory Committee Recommends Truvada for Prevention of HIV Sexual Transmission
- Details
- Category: HIV Prevention
- Published on Thursday, 10 May 2012 00:00
On May 10, 2012, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) decisively recommended approval of Truvada -- Gilead Sciences' tenofovir/emtricitabine combination pill -- for pre-exposure prophylaxis (PrEP) to prevent sexual transmission of HIV.
More Articles...
- Long-Term Analysis Confirms Elevated HIV Risk for Some Participants in Step Vaccine Study
- Pfizer Halts Phase 3 Trial of Pregabalin (Lyrica) for HIV Neuropathy Pain
- FDA Committee Will Consider Approval of Truvada for HIV PrEP this Thursday
- WHO Releases Guidelines for HIV Serodiscordant Couples
- FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children
